Posted by Michael Wonder on 05 Aug 2015
Enzalutamide in prostate cancer: hints of added benefit
5 December 2013 - Enzalutamide (Xtandi) has been approved since June 2013 for men with metastatic prostate cancer in whom the commonly used hormone blockade is no longer effective and who have already been treated with the cytostatic drug docetaxel. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the IQWiG examined whether this new drug offers an added benefit over the appropriate comparator therapy specified by the Federal Joint Committee (G-BA).
In comparison with \"best supportive care\", IQWIG found there is a hint of a major added benefit in patients whose internal organs are free of metastases of the tumour. In patients with such visceral metastases, the extent of added benefit is \"considerable\".For more details, go to: https://www.iqwig.de/en/press/press_releases/press_releases/enzalutamide_in_prostate_cancer_hints_of_added_benefit.5348.html
Posted by:
Michael Wonder
Posted in:
